Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 21825174)

1.

Leukocyte composition of human breast cancer.

Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2796-801. doi: 10.1073/pnas.1104303108. Epub 2011 Aug 8.

3.

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival.

Ladoire S, Mignot G, Dabakuyo S, Arnould L, Apetoh L, Rébé C, Coudert B, Martin F, Bizollon MH, Vanoli A, Coutant C, Fumoleau P, Bonnetain F, Ghiringhelli F.

J Pathol. 2011 Jul;224(3):389-400. doi: 10.1002/path.2866. Epub 2011 Mar 25.

PMID:
21437909
4.

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.

Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A.

Cancer. 2008 Sep 15;113(6):1387-95. doi: 10.1002/cncr.23712.

5.

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma.

Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC.

J Immunol. 2002 Sep 1;169(5):2756-61.

6.

Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.

Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V.

Eur Cytokine Netw. 2000 Jun;11(2):217-24.

PMID:
10903800
7.

Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner GE.

Lab Invest. 1992 Jan;66(1):96-107.

PMID:
1370561
8.

Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.

Baxevanis CN, Dedoussis GV, Papadopoulos NG, Missitzis I, Stathopoulos GP, Papamichail M.

Cancer. 1994 Aug 15;74(4):1275-82.

PMID:
7914469
9.

The peripheral blood leukocyte phenotype in patients with breast cancer: effect of doxorubicin/paclitaxel combination chemotherapy.

Melichar B, Tousková M, Dvorák J, Jandík P, Kopecký O.

Immunopharmacol Immunotoxicol. 2001 May;23(2):163-73.

PMID:
11417845
10.

Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer.

Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, Kanomata N, Kawaguchi A, Akiba J, Naito Y, Ohshima K, Yano H.

Hum Pathol. 2012 Oct;43(10):1688-94. doi: 10.1016/j.humpath.2011.12.013. Epub 2012 Apr 17.

PMID:
22516244
11.

Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy.

Murta EF, de Andrade JM, Falcão RP, Bighetti S.

Tumori. 2000 Sep-Oct;86(5):403-7.

PMID:
11130570
12.

Activation of tumor-infiltrating antigen presenting cells by high intensity focused ultrasound ablation of human breast cancer.

Xu ZL, Zhu XQ, Lu P, Zhou Q, Zhang J, Wu F.

Ultrasound Med Biol. 2009 Jan;35(1):50-7. doi: 10.1016/j.ultrasmedbio.2008.08.005. Epub 2008 Oct 31.

PMID:
18950932
13.

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer.

West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH.

Breast Cancer Res. 2011;13(6):R126. doi: 10.1186/bcr3072. Epub 2011 Dec 8.

14.

Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas.

Pupa SM, Bufalino R, Invernizzi AM, Andreola S, Rilke F, Lombardi L, Colnaghi MI, Ménard S.

J Clin Oncol. 1996 Jan;14(1):85-94.

PMID:
8558226
15.

Minimal recruitment and activation of dendritic cells within renal cell carcinoma.

Troy AJ, Summers KL, Davidson PJ, Atkinson CH, Hart DN.

Clin Cancer Res. 1998 Mar;4(3):585-93.

16.

Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells.

Ladoire S, Arnould L, Apetoh L, Coudert B, Martin F, Chauffert B, Fumoleau P, Ghiringhelli F.

Clin Cancer Res. 2008 Apr 15;14(8):2413-20. doi: 10.1158/1078-0432.CCR-07-4491.

17.

Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors.

Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquère K, Badoual C, Damotte D, Validire P, Maubec E, Delongchamps NB, Cazes A, Gibault L, Garcette M, Dieu-Nosjean MC, Zerbib M, Avril MF, Prévost-Blondel A, Randriamampita C, Trautmann A, Bercovici N.

PLoS One. 2011 Mar 7;6(3):e17621. doi: 10.1371/journal.pone.0017621.

18.

Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.

Ginzkey C, Eicker SO, Marget M, Krause J, Brecht S, Westphal M, Hugo HH, Mehdorn HM, Steinmann J, Hamel W.

Cancer Immunol Immunother. 2010 Apr;59(4):541-51. doi: 10.1007/s00262-009-0771-y. Epub 2009 Oct 2.

PMID:
19798500
19.

Immune cell quantitation in normal breast tissue lobules with and without lobulitis.

Degnim AC, Brahmbhatt RD, Radisky DC, Hoskin TL, Stallings-Mann M, Laudenschlager M, Mansfield A, Frost MH, Murphy L, Knutson K, Visscher DW.

Breast Cancer Res Treat. 2014 Apr;144(3):539-49. doi: 10.1007/s10549-014-2896-8. Epub 2014 Mar 5.

20.

Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas.

Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V.

Cancer Immunol Immunother. 1986;23(3):169-78.

PMID:
3024832
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk